HIV Department, World Health Organization, Geneva, Switzerland.
HIV Department, World Health Organization, Geneva, Switzerland.
Lancet HIV. 2019 Sep;6(9):e623-e631. doi: 10.1016/S2352-3018(19)30193-6.
Despite considerable progress in paediatric HIV treatment and timely revision of global policies recommending the use of more effective and tolerable antiretroviral regimens, optimal antiretroviral formulations for infants, children, and adolescents remain limited. The Paediatric Antiretroviral Drug Optimization group reviews medium-term and long-term priorities for antiretroviral drug development to guide industry and other stakeholders on formulations most needed for low-income and middle-income countries. The group convened in December, 2018, to assess progress since the previous meeting and update the list of priority formulations. Issues relating to drug optimisation for neonatal prophylaxis and paediatric treatment, and those relating to the investigation of novel antiretrovirals in adolescents and pregnant and lactating women were also discussed. Continued focus on identifying, prioritising, and providing access to optimal antiretroviral formulations suitable for infants, children, and adolescents is key to ensuring that global HIV treatment targets can be met.
尽管在儿科艾滋病毒治疗方面取得了相当大的进展，并且及时修订了建议使用更有效和更耐受的抗逆转录病毒方案的全球政策，但适合婴儿、儿童和青少年的最佳抗逆转录病毒制剂仍然有限。儿科抗逆转录病毒药物优化小组审查了抗逆转录病毒药物开发的中期和长期优先事项，以指导行业和其他利益攸关方关注最需要低收入和中等收入国家的制剂。该小组于 2018 年 12 月举行会议，评估上次会议以来的进展情况，并更新优先制剂清单。会议还讨论了与新生儿预防和儿科治疗的药物优化以及与青少年、孕妇和哺乳期妇女的新型抗逆转录病毒药物研究有关的问题。继续重点确定、优先考虑和提供适合婴儿、儿童和青少年的最佳抗逆转录病毒制剂并确保获得这些制剂，是实现全球艾滋病毒治疗目标的关键。
